Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Non-Current Debt (2020 - 2023)

C4 Therapeutics has reported Non-Current Debt over the past 4 years, most recently at $8.6 million for Q1 2023.

  • For Q1 2023, Non-Current Debt fell 15.43% year-over-year to $8.6 million; the TTM value through Mar 2023 reached $8.6 million, down 15.43%, while the annual FY2022 figure was $9.2 million, 14.61% down from the prior year.
  • Non-Current Debt for Q1 2023 was $8.6 million at C4 Therapeutics, down from $9.2 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $10.8 million in Q4 2021 and troughed at $8.6 million in Q1 2023.
  • A 4-year average of $9.9 million and a median of $10.2 million in 2022 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: grew 7.2% in 2021 and later dropped 15.43% in 2023.
  • Year by year, Non-Current Debt stood at $10.1 million in 2020, then rose by 7.12% to $10.8 million in 2021, then decreased by 14.61% to $9.2 million in 2022, then dropped by 6.24% to $8.6 million in 2023.
  • Business Quant data shows Non-Current Debt for CCCC at $8.6 million in Q1 2023, $9.2 million in Q4 2022, and $9.1 million in Q3 2022.